The JAK inhibitor tofacitinib (Xeljanz) provides improvement in patient-reported dermatologic symptoms and quality of life sustained for up to a year in patients with psoriatic arthritis, a new study shows. An analysis of patient reported dermatologic endpoints from two PsA studies – OPAL Broaden and OPAL Beyond – found that tofacitinib was more effective than ...
Tofacitinib improves dermatologic symptoms and QoL in PsA
By Michael Woodhead
14 Apr 2020